Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 24 2021 - 10:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2021
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 24 March 2021, London UK
Moncef Slaoui Departs Galvani Bioelectronics Board of
Directors
The Board of Directors of GlaxoSmithKline plc ("GSK"), the majority
shareholder of Galvani Bioelectronics ("Galvani"), today announced
the termination of Moncef Slaoui as Chair of the Galvani Board of
Directors, effective immediately.
The termination follows the receipt of a letter containing
allegations of sexual harassment and inappropriate conduct towards
an employee of GSK by Dr. Slaoui, which occurred several years ago
when he was an employee of GSK. Upon receipt of the letter, the GSK
Board immediately initiated an investigation with an experienced
law firm to investigate the allegations. The investigation of Dr.
Slaoui's conduct substantiated the allegations and is
ongoing.
Dr. Slaoui's behaviours are wholly unacceptable. They represent an
abuse of his leadership position, violate company policies, and are
contrary to the strong values that define GSK's culture. The
company expects everyone at GSK to behave in accordance with its
values, especially its leaders where its standards are the highest.
Sexual harassment and any abuse of leadership position are strictly
prohibited and will not be tolerated.
Christopher Corsico, SVP Development at GSK and a current member of
the Galvani Board, has been appointed as the new Chair of the Board
of Galvani. In addition, Amy Altshul, SVP Legal, R&D and Global
Commercial Franchises at GSK, has also been appointed to the
Board.
GSK's leadership is firmly committed to building a safe and
respectful environment for every employee. The company has
established policies and resources to manage issues related to
workplace safety and conduct while protecting the privacy and
wellbeing of its employees. Over the last few years, it has worked
hard to prioritise and enhance efforts to ensure that all employees
feel respected and included.
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
About Galvani Bioelectronics
Galvani Bioelectronics is a medical research company dedicated to
the development of bioelectronic medicines to treat chronic
diseases. Formed through a partnership between two global
healthcare companies, GlaxoSmithKline (GSK) and Verily Life
Sciences (formerly Google Life Sciences), a subsidiary of Alphabet
Inc. in 2016, Galvani Bioelectronics combines life science
knowledge with expertise in software and electronics for clinical
applications.
|
GSK enquiries:
|
|
|
|
|
Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Analyst/Investor enquiries:
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such
factors include, but are not limited to, those described in the
Company's Annual Report on Form 20-F for 2020 and any impacts of
the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
24, 2021
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024
